Ruxolitinib, the third most-screened medicine, is known for inhibiting JAK1 and JAK2 and thereby inhibiting tumor invasion and tumorigenesis in human GBM, and it was also employed during COVID-19 for combined antiviral and anti-inflammatory therapy [46,47]. This evidence concerns the gene JAK1 and COVID-19.